Dr. Chengguo Xing

Professor of Medicinal Chemistry, University of Florida

Has dedicated 23 years of research on kava — spanning pharmacognosy, medicinal chemistry, pharmacology, toxicology, analytical chemistry, and clinical translation — particularly for AB-Free Kava’s safety, its potential in cancer, and holistic resilience improvement related to cigarette use. His research has been supported by NCI, NCCIH, the Florida Department of Health, Lung Cancer Research Funding, and many other organizations.

Dr. Pramod Upadhyaya

Professor of Medicinal Chemistry, University of Florida

Has dedicated 23 years of research on kava — spanning pharmacognosy, medicinal chemistry, pharmacology, toxicology, analytical chemistry, and clinical translation — particularly for AB-Free Kava’s safety, its potential in cancer, and holistic resilience improvement related to cigarette use. His research has been supported by NCI, NCCIH, the Florida Department of Health, Lung Cancer Research Funding, and many other organizations.

Dr. Junxuan Lu

​Bernard B. Brodie Professor, Neuroscience & Experimental Therapeutics, Penn State University

His research focuses on understanding the causes of prostate cancer and developing natural preventive agents, including angelica, selenium, and AB-Free Kava. He has led multiple clinical trials of various natural products in preventing prostate cancer recurrence.

Dr. Pablo Leitzman

Internist, St. Paul, Minnesota

An internist affiliated with multiple hospitals in the area, including Regions Hospital and University Medical Center–New Orleans. He received his medical degree from the University of Minnesota Medical School and has been in practice between 6–10 years. He has contributed to the discovery and development of AB-Free Kava and its preclinical evaluation against lung tumorigenesis.